MADISON,
Wis., June 12, 2024 /PRNewswire/ -- Accuray
Incorporated (NASDAQ: ARAY) announced today that the registration
dossier for the Accuray Precision® Treatment Planning
System (TPS) has been approved by the Chinese National Medical
Products Administration (NMPA). The Accuray Precision TPS is now
available for use with the CNNC-Accuray joint venture
Tomo® C radiation therapy system and in combination,
will provide medical care teams with a new option for delivering
extremely precise and accurate radiotherapy treatments, ultimately
expanding access to care for more cancer patients in China.
"We couldn't be more pleased about the approval of the Accuray
Precision Treatment Planning System and the potential it
represents, in combination with the Tomo C System, for cancer
patients in China, a country which
accounted for approximately 25 percent of new cancer cases
diagnosed worldwide in 20201. With this approval our
China joint venture can begin
shipping the Tomo C System to their end customers, an important
step forward in helping to address an unmet need for precision
radiation therapy," said Suzanne
Winter, president and CEO of Accuray.
Continued Ms. Winter, "Customers in China who use our organization's
CyberKnife®, Radixact® and
TomoTherapy® Systems are familiar with the Accuray
Precision Treatment Planning System, a powerful, full-featured
system that enables clinicians to efficiently generate high quality
radiation therapy treatment plans. The availability of the
treatment planning solution for the Tomo C System, a domestic made
radiation therapy delivery device, will expand our portfolio in
China and enhance our access in
the regional Type B market."
The Accuray Precision TPS was developed to facilitate the
creation and adaptation of precise treatment plans in less time.
The planning solution enables clinicians to routinely incorporate
modifications to treatment planning into the course of treatment to
account for changes in tumor size, shape and location – as well as
subtle changes in the location of organs and other healthy tissue –
thereby increasing treatment precision.
The Tomo C platform features helical imaging and radiation
delivery. With fully-integrated treatment planning, centralized
data management and ultra-precise treatment delivery using patented
beam-shaping technology, the system enables greater control of the
radiation dose so it conforms precisely to the tumor and helps
minimize dose to healthy tissue. The system is designed to enable
medical care teams to optimize outcomes for standard radiation
therapy indications including breast, prostate, lung, and head and
neck cancers, in addition to complex treatments such as total
marrow irradiation.
About Accuray
Accuray is committed to expanding the powerful potential of
radiation therapy to improve as many lives as possible. We invent
unique, market-changing solutions that are designed to deliver
radiation treatments for even the most complex cases—while making
commonly treatable cases even easier—to meet the full spectrum of
patient needs. We are dedicated to continuous innovation in
radiation therapy for oncology, neuro-radiosurgery,
and beyond, as we partner with clinicians and administrators,
empowering them to help patients get back to their lives,
faster. Accuray is headquartered in Madison, Wisconsin, with facilities worldwide.
To learn more, visit www.accuray.com or follow us
on Facebook, LinkedIn,
Twitter, and YouTube.
Safe Harbor Statement
Statements made in this press release that are not statements of
historical fact are forward-looking statements and are subject to
the "safe harbor" provisions of the Private Securities Litigation
Reform Act of 1995. Forward-looking statements in this press
release relate, but are not limited, to expectations and goals
regarding new products, services and innovations, expectations
regarding our joint venture, and patient experiences and patient
outcomes. These risks and uncertainties include, but are not
limited to, the effect of the current global economic environment,
including in connection to the COVID-19 pandemic, on the operations
of the company and those of its customers and suppliers; the
company's ability to achieve widespread market acceptance of its
products; the company's ability to develop new products or improve
existing products to meet customers' needs; the company's ability
to anticipate or keep pace with changes in the marketplace and the
direction of technological innovation and customer demands;
reliance on third party collaborators, partnerships, strategic
alliances and joint ventures; and such other risks identified under
the heading "Risk Factors" in company's quarterly report on Form
10-Q, filed with the Securities and Exchange Commission (the "SEC")
on May 8, 2024, and as updated
periodically with the company's other filings with the SEC.
Forward-looking statements speak only as of the date the
statements are made and are based on information available to the
company at the time those statements are made and/or management's
good faith belief as of that time with respect to future events.
The company assumes no obligation to update forward-looking
statements to reflect actual performance or results, changes in
assumptions or changes in other factors affecting forward-looking
information, except to the extent required by applicable securities
laws. Accordingly, investors should not put undue reliance on any
forward-looking statements.
Media Contact:
Beth Kaplan
Public Relations Director, Accuray
+1 (408)
789-4426
bkaplan@accuray.com
1https://pubmed.ncbi.nlm.nih.gov/37755589/#:~:text=A%20total%20of%204%2C546%2C400%20new,leading%20cancer%20types%20in%20China.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/accuray-announces-approval-of-the-accuray-precision-treatment-planning-system-by-chinas-national-medical-products-administration-302170420.html
SOURCE Accuray Incorporated
